The overall objective of the proposed research is to investigate the inborn errors and molecular genetics of the four human cytosolic heme biosynthetic enzymes, delta-aminolevulinic acid dehydratase (ALA-D), hydroxymethylbilane synthase (HMB-S), uroporphyrinogen III synthase (URO-S) and uroporphyrinogen decarboxylase (URO-D). Using the full-length hepatic cDNAs for ALA-D, HMB-S, URO-S and URO-D which have been cloned and sequenced in this laboratory, their respective full-length erythroid cDNAs will be isolated and characterized for identification of tissue-specific sequences in their 5' or 3' regions, determination of their respective cap sites and for prokaryotic expression of the active enzymes. Sub-chromosomal regional localization for HMB- S and URO-S will be assigned by somatic cell and in situ hybridization. Genomic sequences encoding all four enzymes will be isolated; the 5' and 3' regions as well as the intron-exon boundaries will be sequenced and compared. For studies of transcription, chimeric constructs of the genomic 5'-flanking sequences of each gene and the bacterial chloramphenicol acetyltransferase gene will be transfected into K562 erythroid and HepG2 hepatic cells. Deletions and substitution mutations in specific 5' regions and DNase I protection experiments with hepatic and erythroid nuclear extracts will be performed to identify transcriptional regulatory elements and nuclear factors involved in the tissue-specific expression of these genes. The nature of the molecular lesions in unrelated patients with ALA-D deficiency, acute intermittent porphyria (AIP) and cogenital erythropoietic porphyria (CEP) will be determined. Efforts will be directed to identify informative RFLPs for the precise diagnosis of heterozygotes for AIP and porphyria cutanea tarda (PCT. The biochemical and molecular abnormalities in cats with HMB-S dificiency will be characterized. This animal model will permit the unique opportunity to evaluate the metabolic effects of therapeutic modalities, including bone marrow transplantation and retroviral-mediated gene transfer. These studies should provide 1) increased understanding of the structure, organization and tissue-specific regulation of these heme biosynthetic enzymes, 2) delineation of the molecular lesions in these disorders as well as 3) new methods for the precise diagnosis and potential therapy of these inborn errors of heme biosynthess.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK026824-12
Application #
3228048
Study Section
Mammalian Genetics Study Section (MGN)
Project Start
1980-04-01
Project End
1993-03-31
Budget Start
1991-04-01
Budget End
1992-03-31
Support Year
12
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Type
Schools of Medicine
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10029
Salameh, H; Sarairah, H; Rizwan, M et al. (2018) Relapse of porphyria cutanea tarda after treatment with phlebotomy or 4-aminoquinoline antimalarials: a meta-analysis. Br J Dermatol 179:1351-1357
Clavero, Sonia; Ahuja, Yuri; Bishop, David F et al. (2013) Diagnosis of feline acute intermittent porphyria presenting with erythrodontia requires molecular analyses. Vet J 198:720-2
Balwani, Manisha; Desnick, Robert J (2012) The porphyrias: advances in diagnosis and treatment. Hematology Am Soc Hematol Educ Program 2012:19-27
Balwani, Manisha; Desnick, Robert J (2012) The porphyrias: advances in diagnosis and treatment. Blood 120:4496-504
Hasanoglu, Alev; Balwani, Manisha; Kasapkara, Ci?dem S et al. (2011) Harderoporphyria due to homozygosity for coproporphyrinogen oxidase missense mutation H327R. J Inherit Metab Dis 34:225-31
Machaczka, Maciej; Klimkowska, Monika; Regenthal, Sofie et al. (2011) Gaucher disease with foamy transformed macrophages and erythrophagocytic activity. J Inherit Metab Dis 34:233-5
Clavero, Sonia; Bishop, David F; Giger, Urs et al. (2010) Feline congenital erythropoietic porphyria: two homozygous UROS missense mutations cause the enzyme deficiency and porphyrin accumulation. Mol Med 16:381-8
Cantatore-Francis, Julie L; Cohen-Pfeffer, Jessica; Balwani, Manisha et al. (2010) Hepatoerythropoietic porphyria misdiagnosed as child abuse: cutaneous, arthritic, and hematologic manifestations in siblings with a novel UROD mutation. Arch Dermatol 146:529-33
Yasuda, Makiko; Bishop, David F; Fowkes, Mary et al. (2010) AAV8-mediated gene therapy prevents induced biochemical attacks of acute intermittent porphyria and improves neuromotor function. Mol Ther 18:17-22
Bishop, David F; Schneider-Yin, Xiaoye; Clavero, Sonia et al. (2010) Congenital erythropoietic porphyria: a novel uroporphyrinogen III synthase branchpoint mutation reveals underlying wild-type alternatively spliced transcripts. Blood 115:1062-9

Showing the most recent 10 out of 56 publications